CEACAM1 expression in pancreatic endocrine tumors.
Standard
CEACAM1 expression in pancreatic endocrine tumors. / Serra, Stefano; Asa, Sylvia L; Bamberger, Ana-Maria; Wagener, Christoph; Chetty, Runjan.
in: APPL IMMUNOHISTO M M, Jahrgang 17, Nr. 4, 4, 2009, S. 286-293.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CEACAM1 expression in pancreatic endocrine tumors.
AU - Serra, Stefano
AU - Asa, Sylvia L
AU - Bamberger, Ana-Maria
AU - Wagener, Christoph
AU - Chetty, Runjan
PY - 2009
Y1 - 2009
N2 - The aim of this study was to examine the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in pancreatic endocrine tumors (PETs) and to correlate it with clinicopathologic parameters. Sixty-nine PETs were examined for tumor size, necrosis, local peripancreatic invasion and lymphovascular invasion, lymph node, and liver metastasis. The mitotic count, expressed per 10 high-power fields (HPF) and MIB1 index were assessed and tumors were classified according to the World Health Organization classification. A tissue microarray was constructed and stained with an extensive panel of endocrine markers and CEACAM1. Twenty-nine tumors were from males and 40 from females, age range: 23 to 80 years (mean 52.4 y), tumor size ranged from 0.8 to 11 cm (mean 3.5 cm), 8 patients had multiple endocrine neoplasia 1 syndrome, and 1 had von Hippel-Lindau disease. Twenty tumors demonstrated local invasion, 32 had lymphovascular invasion, 16 had lymph node metastasis, and 10 had liver metastasis. CEACAM1 was positive in 47 cases and negative in 22 cases (31.9%). Ninety percent of the CEACAM1-negative cases had a MIB1 index 2% (P=0.02). 86.4% of the CEACAM1-negative PETs had a mitotic count 2/10 HPF. In addition, 80% of tumors >or=2 cm in diameter were CEACAM positive (P
AB - The aim of this study was to examine the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in pancreatic endocrine tumors (PETs) and to correlate it with clinicopathologic parameters. Sixty-nine PETs were examined for tumor size, necrosis, local peripancreatic invasion and lymphovascular invasion, lymph node, and liver metastasis. The mitotic count, expressed per 10 high-power fields (HPF) and MIB1 index were assessed and tumors were classified according to the World Health Organization classification. A tissue microarray was constructed and stained with an extensive panel of endocrine markers and CEACAM1. Twenty-nine tumors were from males and 40 from females, age range: 23 to 80 years (mean 52.4 y), tumor size ranged from 0.8 to 11 cm (mean 3.5 cm), 8 patients had multiple endocrine neoplasia 1 syndrome, and 1 had von Hippel-Lindau disease. Twenty tumors demonstrated local invasion, 32 had lymphovascular invasion, 16 had lymph node metastasis, and 10 had liver metastasis. CEACAM1 was positive in 47 cases and negative in 22 cases (31.9%). Ninety percent of the CEACAM1-negative cases had a MIB1 index 2% (P=0.02). 86.4% of the CEACAM1-negative PETs had a mitotic count 2/10 HPF. In addition, 80% of tumors >or=2 cm in diameter were CEACAM positive (P
M3 - SCORING: Zeitschriftenaufsatz
VL - 17
SP - 286
EP - 293
JO - APPL IMMUNOHISTO M M
JF - APPL IMMUNOHISTO M M
SN - 1541-2016
IS - 4
M1 - 4
ER -